NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
Completion of enrollment sets the stage for planned interim analysis evaluating event-free survival and potential for regulatory filings, if positive
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005485/en/
“I would like to thank the Alliance for completing the enrollment of the Phase 2 portion despite all of the logistical challenges associated with the pandemic. If the EFS analysis meets the preplanned metric, the data will be transferred confidentially to
About Uproleselan
Discovered and developed by
About
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development and potential benefits and impact of the Company’s drug candidate, uproleselan. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005485/en/
Investor:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: